Company
Fenwal
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
0
510(k), De Novo and PMA
Device trials
3
As lead sponsor, any status
Adverse event reports
17
Received Nov 1, 2025 to Nov 20, 2026
Recall records
10
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Fenwal, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Fenwal.
Latest FDA decisions
No 510(k), De Novo or PMA decisions under this name since 2015.
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Evaluation of the Aurora Xi New Nomogram Software 2.0Pivotal-lookingCompleted
NCT06122935 · 6,735 participants · Start Nov 27, 2023 · Primary completion Apr 19, 2024
Device: Aurora Xi New Nomogram Software 2.0; Aurora Xi Currently Approved Software 1.3 · For: Apheresis Related Hypotension
Sites: Lakeland, Florida; West Des Moines, Iowa; American Fork, Utah
NCT02372877 · 83 participants · Start May 2015 · Primary completion Dec 7, 2017
Device: Amicus Red Cell Exchange in SCD patients · For: Sickle Cell Anemia
Sites: Phoenix, Arizona; Detroit, Michigan; St Louis, Missouri · 6 sites in all
NCT01210716 · 37 participants · Start Sep 2010 · Primary completion May 2011
Device: Therapeutic plasma exchange · For: Autoimmune Diseases; Renal Disorders; Hematologic Disorders and 1 more
Sites: New Haven, Connecticut; Rochester, Minnesota; Charlottesville, Virginia · 4 sites in all
Reports received
17
Received Nov 1, 2025 to Nov 20, 2026. Includes 1 of another or unstated type.
Malfunction reports
5
29% of reports
Injury reports
8
47% of reports
Death reports
3
18% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 1 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 1 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 1 | 0 |
| Nov 24 | 0 | 1 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 1 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 1 | 0 | 0 |
| May 25 | 0 | 0 | 2 | 0 |
| Jun 25 | 1 | 1 | 1 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 1 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 1 | 1 | 0 |
| Dec 25 | 1 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 1 | 1 | 0 |
| Mar 26 | 1 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 3 | 0 | 0 | 0 |
| Jul 26 | 0 | 2 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 3 | 1 | 1 |
| Oct 26 | 0 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
1 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
3 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Amicus MNC Apheresis Kit Double Needle. Component of Amicus Separator multiprocedural apheresis platformOpen, Classified
Z-1254-2023 · Started Feb 14, 2023 · Posted by FDA Mar 15, 2023
Reason given: Potential for centrifuge packs to develop a stress leak for certain lots of Amicus MNC Apheresis kit and Amicus Exchange kit (Therapeutic Kits) on the Amicus Separator.
Cause as FDA categorized it: Process control · Device type: Separator, Automated, Blood Cell And Plasma, Therapeutic (LKN)
- Amicus Exchange Kit Therapeutics. Component of Amicus Separator multiprocedural apheresis platformOpen, Classified
Z-1255-2023 · Started Feb 14, 2023 · Posted by FDA Mar 15, 2023
Reason given: Potential for centrifuge packs to develop a stress leak for certain lots of Amicus MNC Apheresis kit and Amicus Exchange kit (Therapeutic Kits) on the Amicus Separator.
Cause as FDA categorized it: Process control · Device type: Separator, Automated, Blood Cell And Plasma, Therapeutic (LKN)
Z-1343-2021 · Started Feb 25, 2021
Reason given: Some lots of Amicus MNC Apheresis and Amicus Exchange kits have leaking centrifuge packs during a procedure on the Amicus Separator using therapeutic protocols only. The defect is a blood leak at the boot, elbow, or in the channel on the separation chamber of the centrifuge pack.
Cause as FDA categorized it: Under Investigation by firm · Device type: Separator, Automated, Blood Cell, Diagnostic (GKT)
7 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.